SCHEMBL2396285

SCHEMBL2396285

COC(=O)c1ccc(-c2cccoc2=O)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.54
NPC1 O15118 1/20 0.51
TP53 P04637 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PTPN1 P18031 2/20 0.50
PTPRC P08575 1/20 0.50
PTPRF P10586 1/20 0.50
CDC25B P30305 1/20 0.50
PSMD14 O00487 1/20 0.49
CACNA1B Q00975 1/20 0.49
APBA1 Q02410 1/20 0.49
EGFR P00533 1/20 0.49
MAOB P27338 1/20 0.48
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
KDM4E B2RXH2 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46
CA1 P00915 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2398844 0.80 KEAP1 (0.44) KMT2ANPC1TP53RAB9ASMN1; SMN2
SCHEMBL5329593 0.79 KMT2A (0.58) KMT2ANPC1TP53RAB9ASMN1; SMN2
SCHEMBL27708108 0.76 EGFR (0.71) KMT2ARAB9ASMN1; SMN2PTPN1PTPRC
SCHEMBL13232062 0.75 EGFR (0.64) RAB9APTPN1PTPRCPTPRFCDC25B
SCHEMBL28065277 0.74 ESR2 (0.45) KMT2ANPC1TP53RAB9ASMN1; SMN2
SCHEMBL1137507 0.74 MAPK1 (0.55) KMT2ANPC1TP53RAB9ASMN1; SMN2
SCHEMBL21261147 0.74 EGFR (0.62) KMT2AEGFRMEN1KDM4ETSHR
SCHEMBL3312749 0.73 EGFR (0.58) NPC1RAB9APTPN1PTPRCPTPRF
SCHEMBL2035147 0.73 EGFR (0.71) KMT2ARAB9APTPN1PTPRCPTPRF
SCHEMBL68818 0.73 SLC6A3 (0.73) KMT2ARAB9APTPN1PTPRCPTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8022208-B2 Benzene derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-20 US disclosed
US-8022208-B2 Benzene derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-20 US disclosed
US-8022208-B2 Benzene derivative or salt thereof ASTELLAS PHARMA INC. (JP) 2011-09-20 US disclosed
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
EP-1947086-A1 BENZENE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-07-23 EP disclosed
EP-1947086-A1 BENZENE DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2008-07-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054352-A1 BENZENE DERIVATIVE OR SALT THEREOF F12, F2, SERPINC1 KMT2A 1892/4885NPC1 4105/4885TP53 1323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.